Esperion Therapeutics, Inc.
ESPRNASDAQHealthcare● Active
$3.15
+$0.02(+0.64%)
Market Cap$654912465
P/E Ratio—
52W High$4.18
52W Low$0.95
Esperion Therapeutics, Inc.（ESPR）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ESPR · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.02B) | ($0.05B) | ($0.21B) | ($0.23B) | ($0.27B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.01B | $0.02B | $0.02B |
| Change in Working Capital | ($0.01B) | ($0.06B) | $0.01B | ($0.00B) | ($0.05B) |
| Net Cash from Operations | ($0.01B) | ($0.02B) | ($0.14B) | ($0.17B) | ($0.26B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | ($0.06B) | ($0.05B) |
| Sales of Investments | $0.00B | $0.00B | $0.04B | $0.07B | $0.00B |
| Net Cash from Investing | $0.00B | ($0.00B) | $0.04B | $0.01B | ($0.05B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.05B) | $0.04B | $0.00B | $0.00B | ($0.00B) |
| Net Cash from Financing | $0.04B | $0.09B | $0.05B | $0.03B | $0.27B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.01B) | ($0.02B) | ($0.14B) | ($0.17B) | ($0.26B) |
| FCF Margin %(computed) | -3.25% | -7.21% | -116.46% | -231.64% | -336.29% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Esperion Therapeutics, Inc.
关于Esperion Therapeutics, Inc.（ESPR）现金流量表
Esperion Therapeutics, Inc. 2025财年经营活动现金流($0.01B)，自由现金流($0.01B)（FCF利润率-3.25%），资本支出$0.00B。
常见问题
ESPR · 4 问Esperion Therapeutics, Inc. 2025财年自由现金流($0.01B)，同比up45.4%。
ESPR free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10